Diag-Nose.io

Diag-Nose.io, founded in 2020 and headquartered in Melbourne, Australia, is a biotechnology company focused on translating the complexities of the unified airway into precision diagnostic and drug discovery solutions. Their precision medicine technology combines advanced proteomics, computational biology, and AI (machine learning) to create a scalable respiratory biology model. This innovation aims to help clinicians prescribe the right treatments faster and enable researchers to accelerate the development of new therapies. The company’s flagship platform, RhinoMAP™, leverages proteomic data to predict respiratory disease activity, monitor therapy response and predict treatment efficacy in advance, with an initial focus on anti-Th2 biologics.